Computer systems for treating diseases
The present invention relates to computer-implemented methods and system for analyzing a biomarker which cycles in a subject. In some other aspects, the present invention relates to analyzing a biomarker which at least initially increases or decreases in amount in a subject following a treatment for a disease. In further aspects, the present invention relates to computer-implemented methods and systems for determining a preferred time to administer a therapy to treat a disease in a subject. The present invention also relates to computer program product to implement the methods. Further, the present invention relates to methods of determining the timing of treating a disease in a subject in which the immune system is cycling.
1. A computer system for determining a preferred time to administer a therapy to treat a disease characterized by cycling immune system markers, comprising:
1) a point of care device for receiving a sample from a subject and for measuring the level of an acute phase inflammatory marker in the sample; and
2) one or more processors to:
i) estimate the periodicity of cycling of the acute phase inflammatory marker in the subject by obtaining a best-fit curve of measurements of the acute phase inflammatory marker from two or more samples obtained at different times from the subject to a model of the cycling of the acute phase inflammatory marker; and
ii) project the obtained best-fit curve into the future and
iii) output a time period as a preferred time in the future, based on the projected best-fit curve, to administer therapy to treat the disease characterized by cycling immune system markers in the subject.
2. A system for analyzing one or more biomarkers in a sample from a subject, comprising:
a) a point of care device for receiving a sample from a subject and for measuring the level of the one or more biomarkers in the sample; and
b) a computing device operable to:
estimate a periodicity of cycling of the one or more biomarkers by obtaining a best-fit curve of measurements of the one or more biomarkers from two or more samples obtained at different times from the subject to a model of the cycling of the one or more biomarkers;
project the obtained best-fit curve into the future; and
output a time period as a preferred time in the future, based on the projected best-fit curve, to administer therapy to treat a disease characterized by cycling biomarkers in the subject;
wherein the point of care device sends the measurements to the computing device.
3. The system of claim 2 , wherein the computing device is further operable to determine from the estimated periodicity of the cycling a preferred time to administer a therapy to treat a disease in the subject.
4. The system of claim 2 , wherein the point of care device comprises the computing device.
5. The system of claim 2 , wherein the computing device is located remotely from the point of care device.
6. The system of claim 5 , wherein the computing device receives measurements of the one or more biomarkers from the point of care device via a communications network.
7. The system of claim 5 , wherein the point of care device sends the measurements of the one or more biomarkers to a data store for retrieval and the computing device retrieves measurements from the store.
8. The system of claim 2 , wherein the biomarker is an acute phase inflammatory marker.
9. The system of claim 2 , wherein the biomarker is a marker of effector cells or regulator cells.
10. The system of claim 2 , wherein a sample is received from the subject at least once every 3 days, at least once every 2 days, at least once every day, or at least once every 12 hours.
11. The system of claim 2 , wherein the computing device is operable to estimate the periodicity of the one or more biomarkers based on at least one measurement of the one or more biomarkers obtained from the subject not using the point of care device.
12. The system of claim 2 , wherein the levels of two or more different biomarkers are measured, and the periodicity of cycling of the two or more different biomarkers is estimated.
13. The system of claim 2 , wherein the sample is selected from blood, serum, plasma, saliva, sputum, ocular lens fluid, sweat, faeces, urine, mucous, transdermal exudates, and pharyngeal exudates.